Cyclooxygenase-2 in human pathological disease

Advances in Experimental Medicine and Biology

Volumn 507, Issue , 2002, Pages 177-184

  Koki, Alane ^a   Khan, Nasir K ^a   Woerner, B Mark ^a   Dannenberg, A J ^b   Olson, Lisa ^a   Seibert, Karen ^a   Edwards, Dorothy ^a   Hardy, Madorra ^a   Isakson, Peter ^a   Masferrer, Jaime L ^a  

^a PFIZER INC   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 1; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ANIMAL TISSUE; ATHEROSCLEROSIS; BLOOD VESSEL; CANCER; CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DUCTUS ARTERIOSUS; ENDOTHELIUM; EPITHELIUM; FOAM CELL; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INFLAMMATION; INFORMATION PROCESSING; KNEE; MACROPHAGE; NONHUMAN; OSTEOARTHRITIS; OSTEOPHYTE; OVULATION; PANCREAS DUCT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIUM; ENZYMOLOGY; FEMALE; GENERAL ASPECTS OF DISEASE; LUNG TUMOR; METABOLISM; PATHOLOGY; REVIEW;

ANIMALIA;

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DISEASE; FEMALE; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0037769717     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0193-0_28     Document Type: Conference Paper

References (20)

1. G.N. Levy, Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer, FASEB J. 11:234 (1997).
2. H.R. Herschman, Prostaglandin synthase-2, Biochem. Biophys. Acta. 1299:125 (1996).
3. K. Seibert, Y. Zhang, K. Leahy et al., Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain, Proc. Natl. Acad. Sci. USA 91:12013 (1994).
4. R.N. DuBoise, R.S. Abramson, L. Crofford, R.A. Gupta, L.S. Simon et al., Cyclooxygenase in biology and disease, FASEB J. 12:1063 (1998).
5. M. Oshima, J.E. Dinchuck, S.L. Kargman, H. Oshima, B. Hancock, et al., Suppression of intestinal polyposis in APC delta 16 knockout mice by inhibition of cyclooxygenase-2 (COX-2), Cell 87:803 (1996).
6. C.C. Chan, S. Boyce, C. Brideau et al., Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J. Pharmacol. Exp. Ther. 290:551 (1999).
7. L.S. Simon, F.L. Lanza, P.E. Lipsky et al., Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects, Arthritis Rheum. 41(9):1591 (1998).
8. A.T. Koki, K.M. Leahy, and J.L. Masferrer, Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy, Exp. Opin. Invest. Drugs 8(10):1623 (1999).
9. Renal paper
10. J.L. Masferrer, P.C. Isakson, and K. Seibert, Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agent that spare the gastrointestinal tract, Gastroeneterol. Clin. North Am. 25:363 (1996).
11. L.J. Marnett, Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer, Preventive Med. 24:103 (1995).
12. M.J. Reeves, P.A. Newcomb, A. Trentham-Dietz, B.E. Storer, and P.L. Remington, Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women, Cancer Epid. Biomark. Prev. 5:955 (1996).
13. M.J. Thun, M.M. Namboodiri, E.E. Calle, W.D. Flanders, and C.W. Heath, Aspirin use and risk of fatal cancer, Cancer Res. 53:1322 (1993).
14. R.E. Harris, K.K. Namboodiri, and W.B. Farrar, Nonsteroidal antiinflammatory drugs and breast cancer, Epidemiol. 5:138 (1996).
15. D.M. Schreinemachers, and R.B. Everson, Aspirin use and lung, colon, and breast cancer incidence in a prospective study, Epidemiol. 5:138 (1994).
16. D.C. Farrow, T.L. Vaughan, P.D. Hansten et al., Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epid. Biom. & Prev. 7:97 (1998).
17. B.S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K, Seibert, and C.V. Rao, Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis, Cancer Res. 60(2):293 (2000).
18. T. Kawamon, C.V. Rao, K. Seibert, and B.S. Reddy, Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis, Cancer Res. 58:409 (1998).
19. S.M. Fischer, H.H. Lo, G.B. Gordon et al., Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis, Molec. Carcinogenesis 25:231 (1999).
20. J.L. Masferrer, K.M. Leahy, A.T. Koki et al., Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res. (in press).